Therapeutic potential of ghrelin and des-acyl ghrelin against chemotherapy-induced cardiotoxicity

Miki Nonaka; Nagomi Kurebayashi; Takashi Murayama; Masami Sugihara; Kiyoshi Terawaki; Seiji Shiraishi; Kanako Miyano; Hiroshi Hosoda; Shosei Kishida; Kenji Kangawa; Takashi Sakurai; Yasuhito Uezono

doi:10.1507/endocrj.64.S35

International Symposium on Ghrelin and Energy Metabolism Homeostasis

Therapeutic potential of ghrelin and des-acyl ghrelin against chemotherapy-induced cardiotoxicity

Miki Nonaka, Nagomi Kurebayashi, Takashi Murayama, Masami Sugihara, Kiyoshi Terawaki, Seiji Shiraishi, Kanako Miyano, Hiroshi Hosoda, Shosei Kishida, Kenji Kangawa, Takashi Sakurai, Yasuhito Uezono

Author information

Miki Nonaka
Division of Cancer Pathophysiology, National Cancer Center Research Institute, Tokyo 104-0045, Japan
Nagomi Kurebayashi
Department of Cellular and Molecular Pharmacology, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan
Takashi Murayama
Department of Cellular and Molecular Pharmacology, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan
Masami Sugihara
Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan
Kiyoshi Terawaki
Division of Cancer Pathophysiology, National Cancer Center Research Institute, Tokyo 104-0045, Japan
Tsumura Kampo Research Laboratories, Kampo Research & Development Division, Tsumura & Co., Ibaraki 300-1192, Japan
Seiji Shiraishi
Division of Cancer Pathophysiology, National Cancer Center Research Institute, Tokyo 104-0045, Japan
Kanako Miyano
Division of Cancer Pathophysiology, National Cancer Center Research Institute, Tokyo 104-0045, Japan
Hiroshi Hosoda
Department of Regenerative Medicine and Tissue Engineering, National Cerebral and Cardiovascular Center Research Institute, Suita 565-8565, Japan
Shosei Kishida
Department of Biochemistry and Genetics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890-8544, Japan
Kenji Kangawa
National Cerebral and Cardiovascular Center Research Institute, Suita 565-8565, Japan
Takashi Sakurai
Department of Cellular and Molecular Pharmacology, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan
Yasuhito Uezono
Division of Cancer Pathophysiology, National Cancer Center Research Institute, Tokyo 104-0045, Japan
Division of Supportive Care Research, National Cancer Center, Exploratory Oncology Research & Clinical Trial Center, Tokyo 104-0045, Japan

Keywords: Cardiotoxicity, Chemotherapy, Des-acyl ghrelin, Doxorubicin, Ghrelin

JOURNAL FREE ACCESS

2017 Volume 64 Issue Suppl. Pages S35-S39

DOI https://doi.org/10.1507/endocrj.64.S35

Details

Abstract

Cancer was considered an incurable disease for many years; however, with the development of anticancer drugs and state-of-the art technologies, it has become curable. Cardiovascular diseases in patients with cancer or induced by cancer chemotherapy have recently become a great concern. Certain anticancer drugs and molecular targeted therapies cause cardiotoxicity, which limit the widespread implementation of cancer treatment and decrease the quality of life in cancer patients significantly. The anthracycline doxorubicin (DOX) causes cardiotoxicity. The cellular mechanism underlying DOX-induced cardiotoxicity include free-radical damage to cardiac myocytes, leading to mitochondrial injury and subsequent death of myocytes. Recently, circulating orexigenic hormones, ghrelin and des-acyl ghrelin, have been reported to inhibit DOX-induced cardiotoxicity. However, little is known about the molecular mechanisms underlying their preventive effects. In the present study, we show the possible mechanisms underlying the effects of ghrelin and des-acyl ghrelin against DOX-induced cardiotoxicity through in vitro and in vivo researches.

Corresponding author

Register with J-STAGE for free!